These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36978873)

  • 1. Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus.
    Silic-Benussi M; Sharova E; Corradin A; Urso L; Raimondi V; Cavallari I; Buldini B; Francescato S; Minuzzo SA; D'Agostino DM; Ciminale V
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.
    Silic-Benussi M; Sharova E; Ciccarese F; Cavallari I; Raimondi V; Urso L; Corradin A; Kotler H; Scattolin G; Buldini B; Francescato S; Basso G; Minuzzo SA; Indraccolo S; D'Agostino DM; Ciminale V
    Redox Biol; 2022 May; 51():102268. PubMed ID: 35248829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis.
    Silic-Benussi M; Scattolin G; Cavallari I; Minuzzo S; Del Bianco P; Francescato S; Basso G; Indraccolo S; D'Agostino DM; Ciminale V
    Cell Death Dis; 2018 Aug; 9(8):822. PubMed ID: 30069011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
    Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
    Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism.
    Dando I; Pacchiana R; Pozza ED; Cataldo I; Bruno S; Conti P; Cordani M; Grimaldi A; Butera G; Caraglia M; Scarpa A; Palmieri M; Donadelli M
    Free Radic Biol Med; 2017 Dec; 113():176-189. PubMed ID: 28962872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
    Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
    Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
    Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
    Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
    Casadevall D; Hernández-Prat A; García-Alonso S; Arpí-Llucià O; Menéndez S; Qin M; Guardia C; Morancho B; Sánchez-Martín FJ; Zazo S; Gavilán E; Sabbaghi MA; Eroles P; Cejalvo JM; Lluch A; Rojo F; Pandiella A; Rovira A; Albanell J
    Mol Cancer Res; 2022 Jul; 20(7):1108-1121. PubMed ID: 35348729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
    Wong J; Welschinger R; Hewson J; Bradstock KF; Bendall LJ
    Oncotarget; 2014 Nov; 5(21):10460-72. PubMed ID: 25361005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
    Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
    Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
    [No Abstract]   [Full Text] [Related]  

  • 12. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
    Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
    Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway.
    Li R; Ke M; Qi M; Han Z; Cao Y; Deng Z; Qian J; Yang Y; Gu C
    Exp Hematol Oncol; 2022 Oct; 11(1):77. PubMed ID: 36271440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
    Mattoo AR; Joun A; Jessup JM
    Mol Cancer Res; 2019 Jan; 17(1):42-53. PubMed ID: 30201826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
    BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
    Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
    J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTORC1 activation induced proximal tubular damage via the pentose phosphate pathway in lupus nephritis.
    Mao Z; Tan Y; Tao J; Li L; Yu F; Zhao M
    Free Radic Biol Med; 2022 Aug; 189():91-101. PubMed ID: 35863688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Daver N; Boumber Y; Kantarjian H; Ravandi F; Cortes J; Rytting ME; Kawedia JD; Basnett J; Culotta KS; Zeng Z; Lu H; Richie MA; Garris R; Xiao L; Liu W; Baggerly KA; Jabbour E; O'Brien S; Burger J; Bendall LJ; Thomas D; Konopleva M
    Clin Cancer Res; 2015 Jun; 21(12):2704-14. PubMed ID: 25724525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicle inhibition at the primordial stage without increasing apoptosis, with a combination of everolimus, verapamil.
    Pargianas M; Kosmas I; Papageorgiou K; Kitsou C; Papoudou-Bai A; Batistatou A; Markoula S; Salta S; Dalkalitsis A; Kolibianakis S; Tarlatzis BC; Georgiou I; Michaelidis TM
    Mol Biol Rep; 2020 Nov; 47(11):8711-8726. PubMed ID: 33079326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth.
    Tsouko E; Khan AS; White MA; Han JJ; Shi Y; Merchant FA; Sharpe MA; Xin L; Frigo DE
    Oncogenesis; 2014 May; 3(5):e103. PubMed ID: 24861463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.